ReviewCureus2025
Overview of the Clinical Potential of microRNAs in the Detection of Suicide.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Suicide represents a priority clinical challenge because of the lack of specific biological and molecular biomarkers. The development of such markers would, together with clinical findings, allow for a concrete diagnosis. MicroRNAs (miRNAs), because of their stability in biological fluids and their role in gene regulation, emerge as useful candidates to complement traditional clinical evaluation. This narrative review synthesizes evidence on the role of miRNAs as biomarkers in suicide and suicidal behavior, based on reports in brain tissue and fluids such as peripheral blood, integrating data on miRNA regulation and their associated molecular pathways. Several miRNAs, including miR-124, miR-18a, miR-132, miR-185, miR-218, and miR-19a-3p, are consistently dysregulated across multiple studies. These findings suggest that miRNA measurement could complement clinical scales and provide an objective biological marker for suicide risk. Their integration into diagnostic protocols could improve risk stratification and open the door to personalized prevention strategies; however, it is essential to validate miRNA panels in multicenter clinical studies before routine implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.